SCHEMBL4737979

SCHEMBL4737979

CC1(C)CCc2nc(-c3cn(-c4cc(-c5cccc(F)c5)nc(-c5cccc(F)c5)c4)cn3)ccc2C1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 4/20 0.38
KDM5B Q9UGL1 1/20 0.34
HSD11B1 P28845 1/20 0.33
CDC7 O00311 1/20 0.32
PIM1 P11309 1/20 0.32
GSK3B P49841 1/20 0.32
HIPK2 Q9H2X6 1/20 0.32
CLK4 Q9HAZ1 1/20 0.32
PARP10 Q53GL7 1/20 0.32
PARP11 Q9NR21 1/20 0.32
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
DHODH Q02127 1/20 0.31
CYP1A2 P05177 1/20 0.31
MAPKAPK2 P49137 1/20 0.31
PSEN1 P49768 1/20 0.31
PSEN2 P49810 1/20 0.31
APH1B Q8WW43 1/20 0.31
NCSTN Q92542 1/20 0.31
APH1A Q96BI3 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4683613 0.94 GRM5 (0.37) GRM5HCRTR1HCRTR2MAPKAPK2CYP11B2
SCHEMBL4684269 0.90 GRM5 (0.40) GRM5HSD11B1CYP1A2PSEN1PSEN2
SCHEMBL4740959 0.89 GRM5 (0.46) GRM5CYP11B2
SCHEMBL6103021 0.86 GRM5 (0.40) GRM5
SCHEMBL4683088 0.86 GRM5 (0.37) GRM5KDM5BCDC7PIM1GSK3B
SCHEMBL13707004 0.85 GRM5 (0.47) GRM5PARP10PARP11DHODHCYP1A2
SCHEMBL4679880 0.84 CYP2C19 (0.40) CYP11B2HSP90AA1HSP90AB1
SCHEMBL4679372 0.84 GRM5 (0.40) GRM5KDM5BHSD11B1CDC7PIM1
SCHEMBL4680210 0.83 GRM5 (0.42) GRM5KDM5BCDC7PIM1GSK3B
SCHEMBL4680870 0.83 GRM5 (0.41) GRM5CYP1A2CYP11B2HSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1943247-A1 TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Merz Pharma GmbH & Co.KGaA (DE) 2008-07-16 EP claimed
WO-2007023245-A1 TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERZ PHARMA GMBH & CO. KGAA (DE) 2007-03-01 WO claimed
US-20060004001-A1 Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors MERZ PHARMA GMBH & CO., KGAA (DE) 2006-01-05 US claimed
US-20060004001-A1 Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors MERZ PHARMA GMBH & CO., KGAA (DE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004001-A1 Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors GRM1, GRM5, GRM2 GRM5 2/4885KDM5B 1756/4885HSD11B1 2917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.